About Incyte Corp
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.incyte.com/
Frequently Asked Questions
What is the 52-week range for INCY?
The 52-week high is $132.6 and the 52-week low is $82.82.
What is the P/E ratio for INCY?
The Price to Earnings (P/E) ratio is 14.49.
What is the dividend yield for INCY?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 29.60%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 27.71%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.75.
Analyst Recommendation Trends
Wall Street analyst consensus for INCY over the last few months:
Latest INCY News
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q2, starting with Incyte (NASDAQ:INCY).
If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much Today
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.48% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $23.82 billion.
Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $128
Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises the price target from $116 to $128.
INCY or TECH: Which Is the Better Value Stock Right Now?
INCY vs. TECH: Which Stock Is the Better Value Option?
Incyte (NASDAQ:INCY) Combines High Growth Momentum With a Breakout Setup
INCY stock clears high growth momentum and technical screens with strong EPS growth, rising margins, and a constructive chart setup near a potential breakout.
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
Eli Lilly's Olumiant wins FDA nod to treat pediatric patients 12 years of age and older with severe alopecia areata, expanding its U.S. use after strong phase III results.
JP Morgan Maintains Neutral on Incyte, Raises Price Target to $123
JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $120 to $123.
FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss
FDA approves Eli Lilly's once-daily pill Olumiant for adolescents aged 12 and older with severe alopecia areata following Phase 3 trials.
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
The U.S. Food and Drug Administration (FDA) on Friday approved Atebrioz (zilurgisertib) tablets, delivering a new once-daily oral treatment to patients suffering from fibrodysplasia ossificans progressiva (FOP). Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) and Incyte Corporation (NASDAQ:INCY) announced the regulatory milestone, noting the medication helps reduce the volume of new abnormal bone formation in adults and children aged 12 and older. Read Also: Regeneron Secures FDA Approval For Ultra-Rar
HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $152
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $150 to $152.
Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases
Syndax achieved FDA approval for Revuforj in r/r mNPM1 AML and is pursuing pivotal studies to expand into 1st-line AML populations. Read why SNDX is a Strong Buy.
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
FOSTER CITY, Calif. & WILMINGTON, Del., September 25, 2026--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill
The Food and Drug Administration’s target date is Saturday, September 26, for zilurgisertib, a once-daily pill for fibrodysplasia ossificans progressiva, or FOP, in patients 12 and older.
FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients 12+ Years; Atebrioz Recommended Dosage 100mg Once Daily
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-third-treatment-fibrodysplasia-ossificans-progressiva
Incyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data
Incyte has delivered a strong multi year share-price run, so the obvious follow up is whether the current valuation is still grounded in the cash the business is expected to generate. With investors weighing fresh product news against a higher starting price, the question is how much of Incyte's future cash flows are already embedded in today's quote. Over the past 3 years the stock has gained 110.9%, which puts pressure on investors to judge whether the cash flow outlook has risen enough to...
Incyte (INCY) Heads To EADV With New Skin Disease Trial Data
Incyte (NasdaqGS: INCY) plans to present new clinical data on its inflammation and autoimmunity portfolio at the upcoming EADV Congress. The presentation will spotlight updates for Opzelura, ruxolitinib cream, across immune mediated skin diseases studied in recent dermatology trials. Incyte will also feature new findings on povorcitinib, reflecting progress across multiple dermatological indications under investigation. These fresh EADV data drops on Opzelura and povorcitinib only tell part...
6 ‘Moonshot’ Biotech Stocks That Offer Big Risks, Bigger Rewards
Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?
Incyte is gaining momentum, recently outperforming the biotech sector and keeping analysts broadly positive on the stock.
Dow Jones Tech Titan Amazon Eyes Buy Point Amid Battle With Key Support Level
Dow Jones tech titan Amazon stock is battling with a key support level and approaching multiple new buy points.
Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says
Incyte's (INCY) colorectal cancer or CRC programs remain "risky and more long-term," RBC Capital Mar
Discover the top S&P500 movers in Tuesday's pre-market session.
Get insights into the top gainers and losers in the S&P500 index of Tuesday's pre-market session.
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
WILMINGTON, Del., September 22, 2026--Incyte Data at the 2026 EADV Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
RBC Capital Reiterates Sector Perform on Incyte, Maintains $109 Price Target
RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $109 price target.
Incyte To Present Data From Its Inflammation And Autoimmunity Portfolio At The European Academy Of Dermatology And Venereology Conference, September 30-October 3
Oral PresentationsAtopic DermatitisAtopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL)(Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.
FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week
Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.
Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia
Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register ruxolitinib cream (registered as Opzelura® in the U.S. and European Union) in Australia.
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target
Incyte (NASDAQ:INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029. Chief Executive Officer Bill Meury said the company’s pipeline has changed substantially over t
Robinhood Soars, SpaceX Orbits Entry: Five Stocks Near Buy Points
Robinhood stock surged in an end-of-week crypto rally. SpaceX is testing an aggressive entry. They lead five stocks near buy points.
IBD Stock Of The Day Eyes Buy Points As Investors Dig Into Its Pipeline
Incyte is Friday's IBD Stock Of The Day. Shares are testing a trendline within a base. That would offer an early entry into the biotech..
Dow Jones Futures: After S&P 500, Nasdaq Rebound, What's Next? Moderna, AMD, SpaceX Flash Buy Signals.
The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.
Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum
INCY combines Minervini Trend Template strength, 93.53 RS, and high-growth momentum. Technical Rating 9, but watch resistance near 129.93 for breakout.
Dow Jones Futures Rise After Bullish S&P 500, Nasdaq Rebound; Moderna, AMD, SpaceX Flash Buy Signals
The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.
Dow Jones Futures: S&P 500, Nasdaq Rebound Above Key Level; Moderna, AMD, SpaceX Flash Buy Signals
The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.
Dow Jones Futures Fall After S&P 500, Nasdaq Rebound Above Key Level; Moderna, AMD, SpaceX Flash Buy Signals
The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.
MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains?
Mirum and Incyte are now awaiting the FDA’s decision on zilurgisertib, a once-a-day pill for an ultra-rare bone disease.
3 Growth Stocks to Add to Your Roster
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’
CNBC final trades: Pros picked Schwab, Cleveland-Cliffs, UnitedHealth and Incyte; shares posted mixed moves Wednesday.
Is Incyte (INCY) Undervalued After Ontario Backed MINJUVI Access?
Incyte (INCY) drew fresh attention after Ontario agreed to fund MINJUVI for relapsed or refractory follicular lymphoma through its FAST Program, giving eligible patients earlier access while reimbursement reviews continue. For context, Incyte’s share price has climbed 27.0% over the past 90 days and the year-to-date share price return is 23.0%. Meanwhile, the 1-year total shareholder return of 47.1% and 3-year total shareholder return of 106.6% point to momentum that long-term holders have...
Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Incyte Corporation (INCY) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 12:20 PM EDTCompany ParticipantsWilliam Meury - CEO...
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.
Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events
Mirum Pharmaceuticals is technically oversold but is likely to have more major drug pipeline catalysts occur in the coming months. Click for more on MIRM.
1 Cash-Heavy Stock for Long-Term Investors and 2 We Ignore
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Damora Therapeutics: Potential Payday Is A Long Way Off
Damora Therapeutics targets myeloproliferative neoplasms with a pipeline led by DMR-001, now in Phase 1/1b trials. Learn why DMRA stock is a hold.
Incyte: Priced For Success, With No Margin Of Safety
Incyte (INCY) stock rated Sell: valuation assumes high pipeline success.
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?
Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.
Incyte (INCY): 3 Reasons We Love This Stock
Incyte’s 29% return over the past six months has outpaced the S&P 500 by 15.7%, and its stock price has climbed to $119.95 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Profitable Biotech Incyte Forms Handle As Institutional Buyers Load Up On Stock
Incyte stock is trading just below a buy zone just as Big Money is giving it the stamp of approval. Shares popped in July following a strong earnings report that impressed investors. Incyte stock shows an ideal Composite Rating of 99, boosted by steady year-over-year earnings growth and a decent Relative Strength Rating of 88.
Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.25% on an annualized basis producing an average annual return of 17.44%. Currently, Incyte has a market capitalization of $24.69 billion.
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody-drug conjugate (ADC) cancer treatments, today announced the appointment of Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026.
Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program
Incyte (NYSE: INCY) today announced that MINJUVI® (tafasitamab) in the treatment of relapsed or refractory follicular lymphoma (R/R FL) has been funded in the province of Ontario through Ontario's Funding Accelerated for Specific Treatments (FAST) Program. Through this program, eligible patients may gain access to treatment sooner while formal reimbursement processes continue.1,2
Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Incyte Corporation (INCY) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 9:45 AM EDTCompany ParticipantsWilliam Meury - CEO...
Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Incyte Corporation (INCY) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 11:00 AM EDTCompany ParticipantsWilliam Meury - CEO &...
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead
MacroGenics (MGNX) trades below cash with a strong ADC/TCE pipeline and ESMO 2026 catalysts.
Incyte: Solid Strategies For Continued Growth, But A Possible Pullback Looms
Incyte Corporation outperformed, rising 34% versus the S&P 500's 15% since March 2026. Find out why INCY stock is a Hold.
2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | Clancy Paul J | +203 | $121.35 | $24,634 |
| 2026-09-30 | HARRIGAN EDMUND | +206 | $121.35 | $24,998 |
| 2026-09-30 | BAKER BROS. ADVISORS LP | +322 | - | - |
| 2026-09-30 | BAKER BROS. ADVISORS LP | +322 | - | - |
| 2026-09-22 | Gardner David H | -920 | $126.93 | $116,776 |
| 2026-09-15 | CAGNONI PABLO J | -9,233 | - | - |
| 2026-09-15 | CAGNONI PABLO J | -6,477 | - | - |
| 2026-09-15 | CAGNONI PABLO J | -4,551 | - | - |
| 2026-09-15 | CAGNONI PABLO J | -2,957 | - | - |
| 2026-09-15 | CAGNONI PABLO J | -13,985 | $120.49 | $1,685,053 |
| 2026-09-15 | CAGNONI PABLO J | -9,233 | $120.5 | $1,112,577 |
| 2026-09-15 | CAGNONI PABLO J | +9,233 | $71.93 | $664,130 |
| 2026-09-15 | CAGNONI PABLO J | +6,477 | $64.25 | $416,147 |
| 2026-09-15 | CAGNONI PABLO J | +4,551 | $61.18 | $278,430 |
| 2026-09-15 | CAGNONI PABLO J | +2,957 | $61.76 | $182,624 |
| 2026-08-25 | Basi Ramitpal K | -504 | $129.72 | $65,379 |
| 2026-08-19 | CAGNONI PABLO J | -10,801 | $125.56 | $1,356,174 |
| 2026-08-12 | CAGNONI PABLO J | -10,803 | $120.04 | $1,296,792 |
| 2026-08-05 | Mayes Patrick A | -2,207 | - | - |
| 2026-08-05 | Mayes Patrick A | -2,207 | $123.99 | $273,646 |
| 2026-08-05 | Mayes Patrick A | +2,207 | $106.47 | $234,979 |
| 2026-08-05 | CAGNONI PABLO J | -10,640 | $122.69 | $1,305,422 |
| 2026-08-03 | Mayes Patrick A | -6,055 | - | - |
| 2026-08-03 | Mayes Patrick A | -6,055 | $120.43 | $729,204 |
| 2026-08-03 | Mayes Patrick A | +6,055 | $105.43 | $638,379 |
| 2026-07-31 | Mayes Patrick A | -326 | - | - |
| 2026-07-31 | Mayes Patrick A | -85 | - | - |
| 2026-07-31 | Mayes Patrick A | -2,293 | - | - |
| 2026-07-31 | Mayes Patrick A | -1,642 | - | - |
| 2026-07-31 | Mayes Patrick A | -2,623 | - | - |
| 2026-07-31 | Mayes Patrick A | -3,023 | - | - |
| 2026-07-31 | Mayes Patrick A | -1,643 | - | - |
| 2026-07-31 | Mayes Patrick A | -2,864 | - | - |
| 2026-07-31 | Mayes Patrick A | -2,623 | - | - |
| 2026-07-31 | Mayes Patrick A | -9,459 | - | - |
| 2026-07-31 | Mayes Patrick A | -2,072 | - | - |
| 2026-07-31 | Mayes Patrick A | -3,148 | - | - |
| 2026-07-31 | Mayes Patrick A | -2,709 | - | - |
| 2026-07-31 | Mayes Patrick A | -2,284 | - | - |
| 2026-07-31 | Mayes Patrick A | -2,918 | - | - |
| 2026-07-31 | Mayes Patrick A | -2,293 | $119.41 | $273,807 |
| 2026-07-31 | Mayes Patrick A | -326 | $121.69 | $39,671 |
| 2026-07-31 | Mayes Patrick A | -85 | $122.19 | $10,386 |
| 2026-07-31 | Mayes Patrick A | -1,642 | $119.38 | $196,022 |
| 2026-07-31 | Mayes Patrick A | -1,643 | $119.51 | $196,355 |
| 2026-07-31 | Mayes Patrick A | -2,864 | $119.4 | $341,962 |
| 2026-07-31 | Mayes Patrick A | -4,695 | $119.39 | $560,536 |
| 2026-07-31 | Mayes Patrick A | -6,171 | $119.43 | $737,003 |
| 2026-07-31 | Mayes Patrick A | -2,187 | $119.47 | $261,281 |
| 2026-07-31 | Mayes Patrick A | -5,332 | $119.42 | $636,747 |
| 2026-07-31 | Mayes Patrick A | -14,661 | $119.46 | $1,751,403 |
| 2026-07-31 | Mayes Patrick A | +326 | $105.43 | $34,370 |
| 2026-07-31 | Mayes Patrick A | +85 | $106.47 | $9,050 |
| 2026-07-31 | Mayes Patrick A | +2,293 | $90.56 | $207,654 |
| 2026-07-31 | Mayes Patrick A | +1,642 | $85.01 | $139,586 |
| 2026-07-31 | Mayes Patrick A | +2,623 | $83.58 | $219,230 |
| 2026-07-31 | Mayes Patrick A | +3,023 | $83.2 | $251,514 |
| 2026-07-31 | Mayes Patrick A | +1,643 | $80.5 | $132,262 |
| 2026-07-31 | Mayes Patrick A | +2,864 | $77.67 | $222,447 |
| 2026-07-31 | Mayes Patrick A | +2,623 | $74.78 | $196,148 |
| 2026-07-31 | Mayes Patrick A | +9,459 | $72.27 | $683,602 |
| 2026-07-31 | Mayes Patrick A | +2,072 | $71.93 | $149,039 |
| 2026-07-31 | Mayes Patrick A | +3,148 | $68.62 | $216,016 |
| 2026-07-31 | Mayes Patrick A | +2,709 | $61.76 | $167,308 |
| 2026-07-31 | Mayes Patrick A | +2,284 | $64.25 | $146,747 |
| 2026-07-31 | Mayes Patrick A | +2,918 | $61.18 | $178,523 |
| 2026-07-31 | CAGNONI PABLO J | -15,888 | $119.7 | $1,901,794 |
| 2026-07-23 | Heeson Lee | +13,498 | - | - |
| 2026-07-23 | Heeson Lee | +15,423 | - | - |
| 2026-07-23 | Morrissey Michael James | +8,999 | - | - |
| 2026-07-23 | Morrissey Michael James | +6,426 | - | - |
| 2026-07-16 | Hoffman Richard A. | +31,923 | - | - |
| 2026-07-16 | Hoffman Richard A. | +18,487 | - | - |
| 2026-07-16 | Hoffman Richard A. | +7,395 | - | - |
| 2026-07-16 | Gardner David H | +31,923 | - | - |
| 2026-07-16 | Gardner David H | +18,487 | - | - |
| 2026-07-16 | Gardner David H | +7,395 | - | - |
| 2026-07-16 | Basi Ramitpal K | +21,548 | - | - |
| 2026-07-16 | Basi Ramitpal K | +12,479 | - | - |
| 2026-07-16 | Basi Ramitpal K | +4,991 | - | - |
| 2026-07-16 | Mayes Patrick A | +25,538 | - | - |
| 2026-07-16 | Mayes Patrick A | +14,790 | - | - |
| 2026-07-16 | Mayes Patrick A | +5,916 | - | - |
| 2026-07-16 | Issa Mohamed Khairie | +33,918 | - | - |
| 2026-07-16 | Issa Mohamed Khairie | +19,643 | - | - |
| 2026-07-16 | Issa Mohamed Khairie | +7,857 | - | - |
| 2026-07-16 | Issa Mohamed Khairie | -1,093 | $115.01 | $125,706 |
| 2026-07-16 | Tray Thomas | +4,079 | - | - |
| 2026-07-16 | Tray Thomas | +2,834 | - | - |
| 2026-07-16 | Stein Steven H | +42,298 | - | - |
| 2026-07-16 | Stein Steven H | +24,496 | - | - |
| 2026-07-16 | Stein Steven H | +9,798 | - | - |
| 2026-07-16 | Stein Steven H | -1,877 | $114.73 | $215,348 |
| 2026-07-16 | Meury William | +77,148 | - | - |
| 2026-07-16 | Meury William | +80,421 | - | - |
| 2026-07-16 | Meury William | +26,807 | - | - |
| 2026-07-16 | CAGNONI PABLO J | +57,861 | - | - |
| 2026-07-16 | CAGNONI PABLO J | +33,508 | - | - |
| 2026-07-16 | CAGNONI PABLO J | +13,403 | - | - |
| 2026-07-15 | Mayes Patrick A | -1,512 | $115.09 | $174,016 |
| 2026-07-15 | Issa Mohamed Khairie | -1,099 | $115.09 | $126,484 |
| 2026-07-15 | Tray Thomas | -1,098 | $115.09 | $126,369 |
| 2026-07-15 | Stein Steven H | -3,088 | $115.09 | $355,398 |
| 2026-07-15 | Stein Steven H | -28,237 | $113.05 | $3,192,193 |
| 2026-07-15 | CAGNONI PABLO J | -4,950 | $115.09 | $569,696 |
| 2026-07-14 | Mayes Patrick A | -437 | $114.88 | $50,203 |
| 2026-07-14 | Tray Thomas | -692 | $114.88 | $79,497 |
| 2026-07-14 | Stein Steven H | -21,830 | $114.88 | $2,507,830 |
| 2026-07-14 | CAGNONI PABLO J | -17,969 | $114.88 | $2,064,279 |
| 2026-07-02 | Mayes Patrick A | -350 | $116.86 | $40,901 |
| 2026-07-02 | Tray Thomas | -477 | $116.86 | $55,742 |
| 2026-07-02 | Stein Steven H | -2,177 | $116.86 | $254,404 |
| 2026-07-02 | Meury William | -4,779 | $116.86 | $558,474 |
| 2026-06-30 | Clancy Paul J | +252 | $113.36 | $28,567 |
| 2026-06-30 | HARRIGAN EDMUND | +255 | $113.36 | $28,907 |
| 2026-06-30 | BAKER BROS. ADVISORS LP | +400 | - | - |
| 2026-06-30 | BAKER BROS. ADVISORS LP | +400 | - | - |
| 2026-06-08 | High Katherine A | +6,111 | - | - |
| 2026-06-08 | High Katherine A | +1,642 | - | - |
| 2026-06-08 | Clancy Paul J | +6,111 | - | - |
| 2026-06-08 | Clancy Paul J | +1,642 | - | - |
| 2026-06-08 | FOUSE JACQUALYN A | +6,111 | - | - |
| 2026-06-08 | FOUSE JACQUALYN A | +1,642 | - | - |
| 2026-06-08 | BIENAIME JEAN JACQUES | +6,111 | - | - |
| 2026-06-08 | BIENAIME JEAN JACQUES | +1,642 | - | - |
| 2026-06-08 | BRAWLEY OTIS W | +6,111 | - | - |
| 2026-06-08 | BRAWLEY OTIS W | +1,642 | - | - |
| 2026-06-08 | HARRIGAN EDMUND | +6,111 | - | - |
| 2026-06-08 | HARRIGAN EDMUND | +1,642 | - | - |
| 2026-06-08 | BAKER BROS. ADVISORS LP | +6,111 | - | - |
| 2026-06-08 | BAKER BROS. ADVISORS LP | +6,111 | - | - |
| 2026-06-08 | BAKER BROS. ADVISORS LP | +1,642 | - | - |
| 2026-06-08 | BAKER BROS. ADVISORS LP | +1,642 | - | - |
| 2026-06-04 | Tray Thomas | -2,639 | - | - |
| 2026-06-04 | Tray Thomas | -2,639 | $100 | $263,900 |
| 2026-06-04 | Tray Thomas | +2,639 | $83.83 | $221,227 |
| 2026-06-01 | CAGNONI PABLO J | -25,469 | $95.59 | $2,434,582 |
| 2026-05-26 | Tray Thomas | -2,051 | $97.35 | $199,665 |
| 2026-05-26 | BIENAIME JEAN JACQUES | -15,000 | - | - |
| 2026-05-26 | BIENAIME JEAN JACQUES | -13,059 | $97.1 | $1,268,029 |
| 2026-05-26 | BIENAIME JEAN JACQUES | +15,000 | $84.53 | $1,267,950 |
| 2026-05-19 | Clancy Paul J | -15,000 | - | - |
| 2026-05-19 | Clancy Paul J | -15,000 | $94.93 | $1,423,950 |
| 2026-05-19 | Clancy Paul J | +15,000 | $84.53 | $1,267,950 |
| 2026-05-08 | BAKER BROS. ADVISORS LP | -15,000 | - | - |
| 2026-05-08 | BAKER BROS. ADVISORS LP | -15,000 | - | - |
| 2026-05-08 | BAKER BROS. ADVISORS LP | +15,000 | $84.53 | $1,267,950 |
| 2026-05-08 | BAKER BROS. ADVISORS LP | +15,000 | $84.53 | $1,267,950 |
| 2026-05-04 | Upadhyay Suketu | +13,171 | - | - |
| 2026-05-04 | Upadhyay Suketu | +38,429 | - | - |
| 2026-05-04 | Upadhyay Suketu | +26,343 | - | - |
| 2026-04-17 | CAGNONI PABLO J | -12,590 | - | - |
| 2026-04-17 | CAGNONI PABLO J | -6,077 | - | - |
| 2026-04-17 | CAGNONI PABLO J | -18,667 | $96.5 | $1,801,366 |
| 2026-04-17 | CAGNONI PABLO J | +12,590 | $71.93 | $905,599 |
| 2026-04-17 | CAGNONI PABLO J | +6,077 | $64.25 | $390,447 |
| 2026-04-15 | Stein Steven H | +39,049 | - | - |
| 2026-04-15 | Meury William | +125,000 | - | - |
| 2026-04-15 | CAGNONI PABLO J | +27,892 | - | - |
| 2026-03-31 | Clancy Paul J | +265 | $94.12 | $24,942 |
| 2026-03-31 | HARRIGAN EDMUND | +269 | $94.12 | $25,318 |
| 2026-03-31 | BAKER BROS. ADVISORS LP | +421 | - | - |
| 2026-03-31 | BAKER BROS. ADVISORS LP | +421 | - | - |
| 2026-03-25 | Trotta Matteo | -537 | $92.23 | $49,528 |
| 2026-03-17 | CAGNONI PABLO J | -11,501 | - | - |
| 2026-03-17 | CAGNONI PABLO J | -7,166 | - | - |
| 2026-03-17 | CAGNONI PABLO J | -18,667 | $94.24 | $1,759,178 |
| 2026-03-17 | CAGNONI PABLO J | +11,501 | $64.25 | $738,939 |
| 2026-03-17 | CAGNONI PABLO J | +7,166 | $61.18 | $438,416 |
| 2026-02-19 | CAGNONI PABLO J | -5,575 | - | - |
| 2026-02-19 | CAGNONI PABLO J | -13,093 | - | - |
| 2026-02-19 | CAGNONI PABLO J | -18,668 | $100.91 | $1,883,788 |
| 2026-02-19 | CAGNONI PABLO J | +5,575 | $61.18 | $341,079 |
| 2026-02-19 | CAGNONI PABLO J | +13,093 | $61.76 | $808,624 |
| 2026-02-02 | Heeson Lee | -111 | $102.67 | $11,396 |
| 2026-02-02 | Morrissey Michael James | -185 | $102.67 | $18,994 |
| 2026-01-20 | Morrissey Michael James | -429 | $102.62 | $44,024 |
| 2026-01-16 | Mayes Patrick A | +4,218 | - | - |
| 2026-01-16 | Issa Mohamed Khairie | +14,237 | - | - |
| 2026-01-16 | Heeson Lee | +8,911 | - | - |
| 2026-01-16 | Trotta Matteo | +8,542 | - | - |
| 2026-01-16 | Tray Thomas | +2,425 | - | - |
| 2026-01-16 | Morrissey Michael James | +7,426 | - | - |
| 2026-01-16 | Stein Steven H | +19,932 | - | - |
| 2026-01-16 | CAGNONI PABLO J | +28,475 | - | - |
| 2026-01-07 | Issa Mohamed Khairie | -10,856 | $109.07 | $1,184,064 |
| 2026-01-06 | Issa Mohamed Khairie | -8,264 | $106.66 | $881,438 |
| 2026-01-05 | Stein Steven H | -15,634 | $101.7 | $1,589,978 |
| 2025-12-31 | Morrissey Michael James | -254 | $98.77 | $25,088 |
| 2025-12-31 | Stein Steven H | -13,292 | $98.77 | $1,312,851 |
| 2025-12-31 | Clancy Paul J | +241 | $98.77 | $23,804 |
| 2025-12-31 | HARRIGAN EDMUND | +245 | $98.77 | $24,199 |
| 2025-12-31 | BAKER BROS. ADVISORS LP | +328 | - | - |
| 2025-12-31 | BAKER BROS. ADVISORS LP | +328 | - | - |
| 2025-12-19 | Tray Thomas | -1,730 | - | - |
| 2025-12-19 | Tray Thomas | -1,044 | - | - |
| 2025-12-19 | Tray Thomas | -2,774 | $100 | $277,400 |
| 2025-12-19 | Tray Thomas | +1,730 | $95.76 | $165,665 |
| 2025-12-19 | Tray Thomas | +1,044 | $95.76 | $99,973 |
| 2025-12-18 | Tray Thomas | -600 | $98.25 | $58,950 |
| 2025-12-17 | Morrissey Michael James | -4,323 | $97.26 | $420,455 |
| 2025-12-16 | Morrissey Michael James | -53,175 | $97.29 | $5,173,396 |
| 2025-12-16 | Morrissey Michael James | -833 | $97.42 | $81,151 |
| 2025-12-11 | Mayes Patrick A | -255 | $94.94 | $24,210 |
| 2025-12-10 | Mayes Patrick A | -5,553 | $95.58 | $530,756 |
| 2025-12-08 | Hoppenot Herve | -2,843 | $96.7 | $274,918 |
| 2025-12-02 | Stein Steven H | -20,105 | $102.51 | $2,060,964 |
| 2025-12-01 | Hoffman Richard A. | +23,665 | - | - |
| 2025-12-01 | Hoffman Richard A. | +43,301 | - | - |
| 2025-12-01 | Hoffman Richard A. | +9,466 | - | - |
| 2025-12-01 | Morrissey Michael James | -326 | $102.04 | $33,265 |
| 2025-12-01 | Stein Steven H | -17,093 | $102.04 | $1,744,170 |
| 2025-12-01 | Stein Steven H | -2,559 | $102.96 | $263,475 |
| 2025-11-24 | Tray Thomas | -600 | $103 | $61,800 |
| 2025-11-21 | Tray Thomas | -169 | $102 | $17,238 |
| 2025-11-17 | Denton Sheila A. | -278 | - | - |
| 2025-11-17 | Denton Sheila A. | -278 | $104.36 | $29,012 |
| 2025-11-17 | Denton Sheila A. | +278 | $64.25 | $17,862 |
| 2025-11-10 | Hoppenot Herve | -187,500 | $105.46 | $19,773,750 |
| 2025-11-05 | Stein Steven H | -1,044 | - | - |
| 2025-11-05 | Stein Steven H | -2,995 | - | - |
| 2025-11-05 | Stein Steven H | -1,194 | - | - |
| 2025-11-05 | Stein Steven H | -5,233 | $102.2 | $534,813 |
| 2025-11-05 | Stein Steven H | +1,044 | $95.76 | $99,973 |
| 2025-11-05 | Stein Steven H | +2,995 | $95.76 | $286,801 |
| 2025-11-05 | Stein Steven H | +1,194 | $83.83 | $100,093 |
| 2025-11-04 | Denton Sheila A. | -598 | - | - |
| 2025-11-04 | Denton Sheila A. | -598 | $101.36 | $60,613 |
| 2025-11-04 | Denton Sheila A. | +598 | $58.06 | $34,720 |
| 2025-11-03 | Heeson Lee | -3,074 | $94.02 | $289,017 |
| 2025-10-15 | Denton Sheila A. | -277 | - | - |
| 2025-10-15 | Denton Sheila A. | -277 | $85.13 | $23,581 |
| 2025-10-15 | Denton Sheila A. | +277 | $64.25 | $17,797 |